Privately-held Humabs BioMed SA of Switzerland has been launched as an independent company in order to commercialise antibody technology that includes a prospective broadly neutralising antibody against Groups 1 and 2 influenza A viruses. ---Subscribe to MedNous to access this article--- Research & University News Company News
